Although our focus is intensive and critical care, we stand behind the hypothesis that data and AI based predictions can be used to dramatically improve outpatient care in specific diagnoses. This is why we have partnered up with Takeda Pharmaceuticals in a scientific consortium looking to improve the outpatient experience for patients suffering from inflammatory bowel disease. In this context, AlgoDx brings AI and regulatory expertise, with the goal to develop medical software that improves patient outcomes.
AlgoDx outpatient clinical pipeline as of July 2022, co-development projects in collaboration with Takeda Pharma
Pre-Clinical R&D | Regulatory clearance EU | Clinical validation in outpatients | Post-marketing clinical follow-up | |||
|---|---|---|---|---|---|---|
| Ulcerative Colitis | ||||||
| Crohn's disease | ||||||
Ongoing Complete | ||||||
Clinical trials – AlgoDx sponsored clinical research
For more information on our ongoing clinical projects, visit clinicaltrials.gov